Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer

comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

Kazuhiro Kitajima, Koji Murakami, Erena Yamasaki, Yasushi Kaji, Mitsugi Shimoda, Keiichi Kubota, Narufumi Suganuma, Kazuro Sugimura

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.

Original languageEnglish
Pages (from-to)452-459
Number of pages8
JournalMolecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging
Volume12
Issue number4
DOIs
Publication statusPublished - 2010 Aug
Externally publishedYes

Fingerprint

Pancreatic Neoplasms
Positron-Emission Tomography
Tomography
Glucose
Recurrence
Contrast Sensitivity
Lymph Nodes
Neoplasm Metastasis
Sensitivity and Specificity

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer : comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. / Kitajima, Kazuhiro; Murakami, Koji; Yamasaki, Erena; Kaji, Yasushi; Shimoda, Mitsugi; Kubota, Keiichi; Suganuma, Narufumi; Sugimura, Kazuro.

In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, Vol. 12, No. 4, 08.2010, p. 452-459.

Research output: Contribution to journalArticle

Kitajima, Kazuhiro ; Murakami, Koji ; Yamasaki, Erena ; Kaji, Yasushi ; Shimoda, Mitsugi ; Kubota, Keiichi ; Suganuma, Narufumi ; Sugimura, Kazuro. / Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer : comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. In: Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging. 2010 ; Vol. 12, No. 4. pp. 452-459.
@article{a1af043e8eae49c2ad5452e1c66e451e,
title = "Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.",
abstract = "PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7{\%}, 95.2{\%}, and 93.3{\%}, respectively, whereas those of PET/non-enhanced CT were 83.3{\%}, 90.5{\%}, and 86.7{\%}, respectively, and those of enhanced CT were 66.7{\%}, 85.7{\%}, and 75.6{\%}, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7{\%}, 50.0{\%}, and 90.4{\%}, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3{\%}, 87.5{\%}, and 83.3{\%}, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.",
author = "Kazuhiro Kitajima and Koji Murakami and Erena Yamasaki and Yasushi Kaji and Mitsugi Shimoda and Keiichi Kubota and Narufumi Suganuma and Kazuro Sugimura",
year = "2010",
month = "8",
doi = "10.1007/s11307-009-0271-7",
language = "English",
volume = "12",
pages = "452--459",
journal = "Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging",
issn = "1536-1632",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer

T2 - comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT.

AU - Kitajima, Kazuhiro

AU - Murakami, Koji

AU - Yamasaki, Erena

AU - Kaji, Yasushi

AU - Shimoda, Mitsugi

AU - Kubota, Keiichi

AU - Suganuma, Narufumi

AU - Sugimura, Kazuro

PY - 2010/8

Y1 - 2010/8

N2 - PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.

AB - PURPOSE: The purpose of this study is to evaluate the accuracy of 2-deoxy-2-[F-18]fluoro-D: -glucose-positron emission tomography (FDG-PET)/computed tomography (CT) with intravenous contrast for depiction of recurrent pancreatic cancer, compared with PET/non-enhanced CT and CT. PROCEDURE: Forty-five patients previously treated for pancreatic cancer underwent PET/CT for suspected recurrence. Lesion status was determined on the basis of histopathology and radiological imaging follow-up. RESULTS: Patient-based analysis showed that sensitivity, specificity, and accuracy of PET/contrast-enhanced CT were 91.7%, 95.2%, and 93.3%, respectively, whereas those of PET/non-enhanced CT were 83.3%, 90.5%, and 86.7%, respectively, and those of enhanced CT were 66.7%, 85.7%, and 75.6%, respectively. In 21 patients whom the final diagnosis was obtained from the histopathologic examination, those figures of PET/contrast-enhanced CT were 94.7%, 50.0%, and 90.4%, respectively. The sensitivity of PET/contrast-enhanced CT in detecting local recurrence, abdominal lymph node metastasis, and peritoneal dissemination were 83.3%, 87.5%, and 83.3%, respectively. CONCLUSION: PET/contrast-enhanced CT is an accurate modality for assessing recurrence of pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=78049330730&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049330730&partnerID=8YFLogxK

U2 - 10.1007/s11307-009-0271-7

DO - 10.1007/s11307-009-0271-7

M3 - Article

VL - 12

SP - 452

EP - 459

JO - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

JF - Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging

SN - 1536-1632

IS - 4

ER -